Dr. Reddy's Laboratories Limited (BOM:500124)
India · Delayed Price · Currency is INR | Market Cap | 1.06T +1.5% |
| Revenue (ttm) | 335.93B +3.2% |
| Net Income | 42.85B -24.2% |
| EPS | 51.42 -24.1% |
| Shares Out | 832.69M |
| PE Ratio | 24.66 |
| Forward PE | 23.96 |
| Dividend | 8.00 (0.63%) |
| Ex-Dividend Date | Jul 10, 2026 |
| Volume | 26,148 |
| Open | 1,267.65 |
| Previous Close | 1,269.00 |
| Day's Range | 1,260.90 - 1,279.55 |
| 52-Week Range | 1,149.00 - 1,376.00 |
| Beta | 0.26 |
| Analysts | Hold |
| Price Target | 1,331.77 (+5.05%) |
| Earnings Date | Jul 24, 2026 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as ... [Read more]
Financial Performance
In fiscal year 2026, Dr. Reddy's Laboratories's revenue was 335.93 billion, an increase of 3.19% compared to the previous year's 325.54 billion. Earnings were 42.85 billion, a decrease of -24.22%.
Financial StatementsAnalyst Summary
According to 39 analysts, the average rating for 500124 stock is "Hold." The 12-month stock price target is ₹1,332, which is an increase of 5.05% from the latest price.
News
Dr. Reddy's Laboratories (RDY) Secures License for XACDURO Distribution
Dr. Reddy's Laboratories (RDY) Secures License for XACDURO Distribution
Innoviva announces distribution, licensing agreement with Dr. Reddy’s
Innoviva Specialty Therapeutics, a subsidiary of Innoviva (INVA), announced that it has entered into an exclusive distribution and licensing agreement with Dr. Reddy’s Laboratories (RDY) for the devel...
Dr. Reddy's Laboratories (RDY) Faces 15% Drop Amid Market Movements
Dr. Reddy's Laboratories (RDY) Faces 15% Drop Amid Market Movements
Stocks to watch on June 15: Aurobindo Pharma, Patanjali Foods, Cyient, Dr Reddy's, JSW Energy, Aditya Birla Capital and more
Indian equities head into Monday's session with a heavy mix of corporate actions, regulatory developments, fundraises and order wins across pharma, power, capital markets and infrastructure. Adding to...
Dr. Reddy's (RDY) Launches Generic Bosutinib Tablets in the U.S.
Dr. Reddy's (RDY) Launches Generic Bosutinib Tablets in the U.S.
Dr. Reddy’s announces first-to-market launch of Bosutinib Tablets 400mg
Dr. Reddy’s (RDY) Laboratories announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif, in the United States, expanding its oncology portfolio and reinforcing ...
Dr. Reddy's Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Bosulif--Dr. Reddy's Laboratories Ltd. announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif® i...
Dr. Reddy's launches Bosutinib Tablets 400mg in the United States
Dr. Reddy’s Laboratories Ltd. has announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States. This launch enhances Dr. Reddy’s oncology por...
Nomura on Pharma May 2026: Torrent leads semaglutide with 19% market share, Sun gains; Alkem and Dr Reddy's lag market
Global brokerage Nomura has highlighted Torrent Pharmaceuticals as the standout performer among its India pharma coverage in May 2026, with the company recording the strongest growth in the Indian Pha...
Dr. Reddy's Laboratories issues 12,100 equity shares under stock options scheme
Dr. Reddy's Laboratories has announced the allotment of 12,100 equity shares to eligible employees following the exercise of stock options under its Employees Stock Options Scheme, 2002, and Employees...
Dr. Reddy's files 20-F annual report with US SEC for fiscal year ended March 31, 2026
Dr. Reddy's Laboratories has filed its Form 20-F annual report with the United States Securities and Exchange Commission (SEC), the company announced on May 30, 2026. The filing contains consolidated…
NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, May 29, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NY...
Dr Reddy’s to ring closing bell at NYSE to mark 25 years of its listing
Dr Reddy’s Laboratories will ring the NYSE closing bell on May 30 to mark 25 years since its 2001 listing, a first for an Asian pharma firm outside Japan.
Dr. Reddy's Laboratories to ring the Closing Bell at NYSE for 25th listing anniversary
Dr. Reddy’s Laboratories Ltd. is set to ring the Closing Bell® at the New York Stock Exchange (NYSE) on May 29, 2026, marking 25 years since its listing. The company…
Dr Reddy’s rolls out oral semaglutide in India
Dr Reddy’s launches oral semaglutide biosimilar Obeda in India for Type 2 diabetes, CDSCO-approved; once-daily tablets priced Rs 99–225 (3/7/14 mg).
Dr. Reddy's (RDY) Introduces Generic Semaglutide Injection in Canada
Dr. Reddy's (RDY) Introduces Generic Semaglutide Injection in Canada
Dr. Reddy’s launches generic Semaglutide injection in Canada
Dr. Reddy’s (RDY) Laboratories announced the launch of its generic Semaglutide Injection in Canada. Dr. Reddy’s is among the first companies to introduce a generic Semaglutide Injection in the Canadia...
Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada
HYDERABAD, India & MISSISSAUGA, Ontario--(BUSINESS WIRE)---- $RDY #DrReddy--Dr. Reddy's Laboratories Ltd. a global pharmaceutical company, today announced the launch of its generic Semaglutide Injecti...
Dr. Reddy's Laboratories launches generic Semaglutide Injection in Canada
Dr. Reddy's Laboratories Ltd., a global pharmaceutical company, has announced the launch of its generic Semaglutide Injection in Canada. This development follows the receipt of the Notice of Complianc...
Pharma Stocks Today, May 15: Dr. Reddy’s Lab rises 1.32%, Lupin gains 1.19%, Strides Pharma falls 2.35%
Pharmaceutical stocks traded mixed on May 15 2026 in the early morning session. The BSE Healthcare index declined 0.15% to 47,037.86, while the broader market showed mild positive movement. The…
Dr. Reddy's Laboratories Q4 Earnings Call Highlights
Dr. Reddy's Laboratories NYSE: RDY reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026 performance, with record annual revenue despite pressure from lower lenalidomi...
Dr Reddy's, Dixon Technology & more: Top stocks to watch today
Morgan Stanley maintained an equal-weight rating on Dr Reddy’s Labs, citing missed Q4FY26 estimates and a slight delay in Semaglutide ramp-up. Kotak Institutional Equities recommended buying Dixon Tec...
Dr Reddy's Laboratories Ltd (RDY) Stock Up 4.2% and Still Undervalued -- GF Score: 90/100
Dr Reddy's Laboratories Ltd (RDY) Stock Up 4.2% and Still Undervalued -- GF Score: 90/100
Dr. Reddy's Laboratories (RDY) Set to Launch Generic Ozempic in Canada
Dr. Reddy's Laboratories (RDY) Set to Launch Generic Ozempic in Canada
Dr Reddy’s Labs Q4 net profit plunges 86%
Dr Reddy’s Labs Q4FY26 net profit fell 86% to Rs 221 crore as revenue dropped 12% to Rs 7,516 crore, hit by lower Revlimid sales in North America.